Wanbury Ltd.
Snapshot View

86.05 -2.75 ▼-3.1%

26 July 2021, 04:00:00 P.M.
Volume: 1,561

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.wanbury.com
Financial Indicators
Market Cap 281.00 Cr.
Earnings per share (EPS) -3.86 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share -32.68 Trailing Twelve Months Ending 2021-03
Price to Book Value -2.63 Calculated using Price: 86.05
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 3.27 Cr. 32,655,498 Shares
FaceValue 10
Company Profile

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

  • Coriminic table
  • Cpink table
  • Nock 2 tab
  • Senasof tab
  • Zevanuron
  • Rabiplus cap
  • Folinine
  • Cpink-s
  • Nuture
  • Adtrol 200mg

Milestones:

2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

  • Wanbury ranks 47th as per ORG-IMS (Jan-2009) 
  • Cpink awarded “Best Brand Launch' by ORG IMS (06-07)  
  • Rabiplus awarded “Best Brand Launch' by ORG IMS (07-08) 
  • World's largest producer of Metformin
  • Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.10%
1 Week
+0.12%
1 Month
-5.34%
3 Month
-13.73%
6 Month
+47.22%
1 Year
+174.92%
2 Year
+435.80%
5 Year
+109.88%
9 years 2012-03 2013-03 2014-09 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -365.97
Return on Capital Employed (%) 0.30 -12.92 -31.06 13.85 15.27 70.48 -2.00 50.26 444.46
Return on Assets (%) -4.95 -11.03 -21.66 0.80 -1.82 15.57 -9.44 -9.00 23.10

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 44 -48 -192 -194 -189 -153 -185 -209 -143
Non Curr. Liab. 272 347 312 298 251 160 106 130 108
Curr. Liab. 466 447 259 265 299 402 348 362 311
Minority Int. 27 27 27 27 27
Equity & Liab. 809 773 406 396 388 409 269 283 275
Non Curr. Assets 584 583 219 215 224 217 192 185 182
Curr. Assets 225 190 187 181 164 192 78 98 94
Misc. Exp. not W/O
Total Assets 809 773 406 396 388 409 269 283 275

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 386 459 662 250 423 434 371 391 367
Other Income 13 5 11 6 1 90 77 12 46
Total Income 400 464 673 256 425 524 448 403 414
Total Expenditure -389 -491 -638 -229 -391 -415 -439 -378 -389
PBIDT 11 -27 35 28 34 108 9 25 25
Interest -40 -37 -48 -19 -32 -36 -31 -40 -33
Depreciation -17 -23 -23 -5 -9 -10 -10 -10 -10
Taxation 0 -3 -1 0 0 0 0
Exceptional Items 8 -89 83
PAT -39 -87 -128 3 -7 62 -32 -25 64

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-09 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 9 87 68 40 43 43 32 30 44
Cash Fr. Inv. -32 -21 -6 -5 -20 -13 -1 -3 64
Cash Fr. Finan. 24 -64 -71 -30 -28 -27 -33 -27 -108
Net Change 2 3 -9 5 -5 3 -2 0 0
Cash & Cash Eqvt 7 10 1 6 2 5 3 3 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 54.93 54.93 54.93 52.13 52.13 52.09 52.09 52.09 39.90
Public 45.07 45.07 45.07 47.87 47.87 47.91 47.91 47.91 60.10
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 76.76 76.76 76.76 76.76 76.76 76.76 76.76 76.76 76.76

Announcements View Details

Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Wanbury Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 12 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
1230
Name of the Signatory :- JITENDRA J GANDHI
Designation :- Company Secretary and Compliance Officer
Mon, 12 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74 (5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 we are enclosing herewith Certificate dated 7th July 2021 issued by M/ s. Link Intime India Pvt. Ltd. Registrar and Share Transfer Agent (RTA) of the Company having SEBI Regn. No. INR000004058 for the quarter ended on 30th June 2021.
Kindly take the same on your records.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%